United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of United Therapeutics stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $475.27, for a total value of $1,901,080.00. Following the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at $61,785.10. This trade represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Performance

UTHR opened at $489.31 on Friday. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $492.62. The company has a market cap of $21.07 billion, a P/E ratio of 18.54, a PEG ratio of 4.81 and a beta of 0.86. The business’s 50-day simple moving average is $452.91 and its 200-day simple moving average is $367.90.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same period in the prior year, the company posted $6.39 earnings per share. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on UTHR shares. HC Wainwright lifted their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Wells Fargo & Company raised their price objective on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Oppenheimer boosted their target price on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. UBS Group upped their target price on United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Finally, Royal Bank Of Canada lifted their price target on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $505.00.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB grew its stake in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the last quarter. Chung Wu Investment Group LLC acquired a new stake in shares of United Therapeutics during the second quarter worth $29,000. Abich Financial Wealth Management LLC purchased a new position in United Therapeutics in the 3rd quarter valued at $44,000. SVB Wealth LLC acquired a new position in United Therapeutics in the 1st quarter valued at $32,000. Finally, WealthCollab LLC increased its stake in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.